A better world with innovative AI-driven drug discovery and development.
2
0
2
2
- 2022.03
- Research Collaboration with JW Pharmaceutical
- 2022.01
- Research Collaboration on Anti-Cancer Drug with Donghwa Pharmaceutical
- 2021.12
- Obtained the 'Technical Evaluation' for Public Listing
- 2021.11
- Anti-Metastasis (OC210/202e) IIT begin (Asan Medical Center, Severance Hospital, Haeundae Paik Hospital) 해운대백병원)
- 2021.10
- Selected TOP10 for 'GO AUSTRIA' Program, organized by Austria Wirtschaftsservice Gesellschaft mbH (AWS)
- 2021.10
- Research Collaboration on Scleroderma with 4P Pharma of Institut Pasteur de Lille
- 2021.10
- 3rd place in China Chongqing Innovation and Entrepreneurship Roadshow Contest
- 2021.09
- ONCOfind AI IIT begin (Kangbuk Samsung Hospital, National Cancer Center)
- 2021.06
- Selected in Skydeck Accelerator, UC Berkeley
- 2021.06
- Obtained Technical Evaluation 'A' rating from Korea Technology Finance Corp (KIBO)
- 2021.06
- Established ONCOCROSS AUSTRALIA Pyt Ltd.
- 2021.05
- Research Collaboration with Columbia University Medical Center
- 2021.04
- Research Collaboration with Cyclica Inc.
- 2021.04
- MOU with HLB on Anti-Cancer Drug Development
- 2021.04
- MOU with Choong Nam University on AI Drug Discovery Research Collaboration
- 2021.04
- MOU with CHA Bundang Medical Center
- 2021.04
- Research Collaboration with Samsung Medical Center
- 2021.03
- Research Collaboration with / SI Investment from Daewoong Pharmaceutical
- 2020.12
- Awarded the 'Best SME Company' for this year from Money Today
- 2020.12
- Awarded the 'Best Entrepreneur' from the Ministry of SMEs and Startups, Government of Korea
- 2020.09
- Research Collaboration with ST Pharm on COVID-19 & Dengue Fever
- 2020.09
- Selected as 'BIG3 R&D' Project with COVID-19 & Infectious Disease
- 2020.08
- Series B Funding Closed (KRW 16.5 billion)
- 2020.08
- MTA with Cancer Research UK
- 2020.06
- OC514 (sarcopenia treatment) License-Out to Korea Pharma
- 2020.06
- Selected as 'TIPS' Business
- 2020.05
- Selected in the Government Sponsored 'Growth Jump' Package
- 2020.05
- Selected as 'SMEs' BIG3 Innovative Growth' Project
- 2020.02
- MOU with Seoul National University on PharmDB-K Research
- 2020.01
- CDA with MD Anderson on Sarcopenia Treatment
- 2020.01
- JPI-289 License-In from Jeil Pharmaceutical
- 2019.10
- Awarded from Ministry of Health and Welfare, Government of Korea
- 2019.09
- Optimal Indication and Biomarker Screening Service for ST Pharm
- 2019.07
- Selected as 'IP Voucher' Business
- 2019.05
- Series A Funding Closed (KRW 6 billion)
- 2018.11
- Selected as TIPS
- 2018.10
- Selected in the Government Sponsored 'Growth Jump' Package
- 2018.10
- MOU with Korea Research Institute of Chemical Technology
- 2017.04
- Selected in the Government Sponsored Cancer Project
- 2016.04
- Obtained 'Venture Company' Status
- 2015.08
- Obtained Research Laboratory Status
- 2015.06
- Established ONCOCROSS CO., LTD,